Kevin Rakin

Kevin Rakin

Founder presso ELUTIA INC.

Patrimonio netto: 8 M $ in data 31/03/2024

63 anni
Health Technology
Finance
Commercial Services

Profilo

Kevin L.
Rakin
is the founder of Helix Therapeutics, Inc. (founded in 2006), Genaissance Pharmaceuticals, Inc. (founded in 1998), HighCape Partners Management LLC (founded in 2013), Elutia, Inc. (founded in 2015), and Cybrexa, Inc. (founded in 2016).
He held various titles at Genaissance Pharmaceuticals, Inc., including President & Chief Executive Officer from 1998 to 2005.
Mr. Rakin is also the founder of HighCape Capital LP.
Mr. Rakin's current job(s) include Chairman & Chief Executive Officer at HighCape Capital Acquisition Corp.
II (since 2021), Chairman at Wellinks, Inc., Director at Cyvek, Inc. (since 2012), Independent Non-Executive Director at Nyxoah SA (since 2016), Director at Convexity Scientific, Inc. (since 2017), President & Director at Aztek Bio LLC, and Director at Quantum-Si, Inc. (since 2020).
Mr. Rakin's former job(s) include Chief Executive Officer at Shire Regenerative Medicine, Inc. (2007-2011), Chief Executive Officer at Canaan Management, Inc. (2006-2007), Chairman & Chief Executive Officer at HighCape Capital Acquisition Corp.
(2020-2021), Chairman at Oramed Pharmaceuticals, Inc. (2016-2022), Chairman at Athena Therapeutics LLC, Director at Clinical Data, Inc., Director at Vion Pharmaceuticals, Inc. (2007-2010), Director at OMRIX Biopharmaceuticals, Inc. (2007-2008), Independent Director at Histogenics Corp.
(2012-2019), Director at Cheetah Medical, Inc., Director at TELA Bio, Inc., Director at Sciona, Inc., Director at QIAGEN Marseille SA, Director at Collagen Matrix, Inc., President at Shire Regenerative Medicine, Inc. (2011-2012), and President-Regenerative Medicine at Shire Plc (2011-2012).
He was also an Advisor at Red Abbey Venture Partners LLC and a Principal at The Stevenson Group (1990-1997).
Mr. Rakin's education includes undergraduate and graduate degrees from the University of Cape Town and an MBA from Columbia Business School.

Partecipazioni note in società pubbliche

SocietàDataNumero di azioniValorizzazioneData di valutazione
01/03/2024 2 909 924 ( 2.39% ) 6 M $ 31/03/2024
18/03/2024 148 500 ( 0.52% ) 2 M $ 31/03/2024
28/12/2023 90 807 ( 0.45% ) 286 042 $ 31/03/2024

Posizioni attive di Kevin Rakin

SocietàPosizioneInizio
ELUTIA INC. Founder 06/08/2015
NYXOAH SA Director/Board Member 29/06/2016
QUANTUM-SI INCORPORATED Director/Board Member 10/06/2020
Founder 01/01/2016
Director/Board Member 01/01/2017
Chief Executive Officer 01/02/2021
Director/Board Member 01/01/2012
Tutte le posizioni attive di Kevin Rakin

Precedenti posizioni note di Kevin Rakin

SocietàPosizioneFine
Consultant / Advisor 23/12/2022
ORAMED PHARMACEUTICALS INC. Chairman 30/06/2022
░░░░ ░░░░ ░░░░░ ░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
Vedi nel dettaglio l'esperienza di Kevin Rakin

Formazione di Kevin Rakin

University of Cape Town Graduate Degree
Columbia Business School Masters Business Admin

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Kevin Rakin

Relazioni

100 +

Relazioni di 1° grado

26

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa5
TELA BIO, INC.

Health Technology

ELUTIA INC.

Health Technology

NYXOAH SA

Health Technology

ORAMED PHARMACEUTICALS INC.

Health Technology

QUANTUM-SI INCORPORATED

Technology Services

Aziende private19

Health Technology

Health Technology

Commercial Services

Health Technology

Finance

Health Technology

Finance

Health Services

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Transportation

Finance

Health Technology

Finance

Health Technology

Health Technology

Vedi le connessioni aziendali